Emicizumab In a Preterm Infant with Severe Hemophilia A – RPTH
RPTH Journal shared a post on LinkedIn about a recent article by Eman Hassan et al, adding:
”Emicizumab in a preterm infant with severe hemophilia A
Emicizumab has transformed prophylaxis in hemophilia A, but data in preterm and very low-birth-weight infants are virtually nonexistent.
What do you do when a baby is born at 30 weeks with severe HA and a high risk of intracranial hemorrhage?
A new case report in RPTH Journal describes exactly this scenario and the multidisciplinary decision-making behind it.
Key details:
- Male infant born at 30+4 weeks to a known HA carrier
- Severe HA confirmed; intracranial hemorrhage excluded on cranial ultrasound
- Emicizumab prophylaxis initiated at just 26 hours of life
- Loading phase completed and maintenance dosing achieved with no bleeding, thrombosis, or adverse events”
Title: Emicizumab prophylaxis in a preterm infant with severe hemophilia A: a case report on the feasibility of early use
Authors: Eman Hassan, Charles Percy, Amna Ahmed, Gillian Lowe, Will Lester, Neil V. Morgan, Jayashree Motwani
Read the Full Article on RPTH Journal
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 7, 2026, 15:45Alejandro Lusilla Lopez: PRF for Complex Anal Fistulae Outcomes
-
Apr 7, 2026, 15:41Edwin Ofori Atta: High-Dose Vitamin C and Vascular Function
-
Apr 7, 2026, 15:32Brad McEwen: Dark Chocolate and Cardiometabolic Health
-
Apr 7, 2026, 14:50Sean O.: The Urgent Need for Blood in the United States
-
Apr 7, 2026, 14:42Samson Kraikue-Quaicoe: The Role of Minor Fractions in Advanced Medical Care Beyond Whole Blood and Primary Components
-
Apr 7, 2026, 14:36Heghine Khachatryan: When Bleeding Speaks – Think Beyond Gynecology
-
Apr 7, 2026, 13:50Annie Bauzon: How to Properly Make a Peripheral Blood Smear
-
Apr 7, 2026, 13:42Timothy Lesaca: How SSRIs Influence Hemostasis Through Platelets
-
Apr 7, 2026, 13:32Bastu Odoka: Storage Lesions – What Really Happens to Stored Blood